NCT02821052View on ClinicalTrials.gov

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

CompletedOBSERVATIONAL

Enrollment

1,355

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

November 24, 2018

Study Completion Date

November 24, 2018

Conditions

Diabetes

Interventions

DRUG

insulin degludec/insulin aspart

Enrolled patients will be treated with Ryzodeg® under routine clinical practice.

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY